EA201270646A1 - Ингибиторы глюкозилцерамидсинтазы - Google Patents

Ингибиторы глюкозилцерамидсинтазы

Info

Publication number
EA201270646A1
EA201270646A1 EA201270646A EA201270646A EA201270646A1 EA 201270646 A1 EA201270646 A1 EA 201270646A1 EA 201270646 A EA201270646 A EA 201270646A EA 201270646 A EA201270646 A EA 201270646A EA 201270646 A1 EA201270646 A1 EA 201270646A1
Authority
EA
Eurasian Patent Office
Prior art keywords
formula
compound
hemitartrate
hemi
tartrate salt
Prior art date
Application number
EA201270646A
Other languages
English (en)
Other versions
EA023923B1 (ru
Inventor
Ханлан Лиу
Крис Уиллис
Рену Бардваж
Диане П. Коупланд
Абизер Харианавала
Джеффри Скелл
Джон Маршалл
Джианмеи Кочлинг
Джерард Палас
Джудит Петершмитт
Крейг Сигел
Сенг Ченг
Original Assignee
Джензим Корпорэйшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43431870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201270646(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Джензим Корпорэйшн filed Critical Джензим Корпорэйшн
Publication of EA201270646A1 publication Critical patent/EA201270646A1/ru
Publication of EA023923B1 publication Critical patent/EA023923B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Описана гемитартратная соль соединения, представленного следующей структурной формулой:(гемитартрат соединения формулы I),которая может быть использована в фармацевтических областях применения; конкретные отдельные кристаллические формы гемитартрата соединения формулы (I), характеризуемые множеством свойств и физических измерений. Также обсуждаются способы получения гемитартрата соединения формулы (I) и его использования для ингибирования глюкозилцерамидсинтазы или снижения содержаний глюкосфинголипидов у субъектов для лечения ряда заболеваний. Также описываются фармацевтические композиции.
EA201270646A 2009-11-27 2010-11-24 Ингибиторы глюкозилцерамидсинтазы EA023923B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26474809P 2009-11-27 2009-11-27
PCT/US2010/057952 WO2011066352A1 (en) 2009-11-27 2010-11-24 An amorphous and a crystalline form of genz 112638 hemitartrat as inhibitor of glucosylceramide synthase

Publications (2)

Publication Number Publication Date
EA201270646A1 true EA201270646A1 (ru) 2013-01-30
EA023923B1 EA023923B1 (ru) 2016-07-29

Family

ID=43431870

Family Applications (3)

Application Number Title Priority Date Filing Date
EA201890254A EA201890254A3 (ru) 2009-11-27 2010-11-24 Ингибиторы глюкозилцерамидсинтазы
EA201592195A EA029990B1 (ru) 2009-11-27 2010-11-24 Способы лечения ингибиторами глюкозилцерамидсинтазы
EA201270646A EA023923B1 (ru) 2009-11-27 2010-11-24 Ингибиторы глюкозилцерамидсинтазы

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EA201890254A EA201890254A3 (ru) 2009-11-27 2010-11-24 Ингибиторы глюкозилцерамидсинтазы
EA201592195A EA029990B1 (ru) 2009-11-27 2010-11-24 Способы лечения ингибиторами глюкозилцерамидсинтазы

Country Status (41)

Country Link
US (6) US11458119B2 (ru)
EP (5) EP3599237B1 (ru)
JP (6) JP2013512252A (ru)
KR (5) KR20220162824A (ru)
CN (5) CN112521366A (ru)
AR (3) AR079152A1 (ru)
AU (3) AU2010324810B2 (ru)
BR (1) BR112012012947B8 (ru)
CA (3) CA2781676C (ru)
CL (2) CL2012001348A1 (ru)
CR (1) CR20120277A (ru)
CY (3) CY1115880T1 (ru)
DK (3) DK2504332T4 (ru)
DO (2) DOP2012000141A (ru)
EA (3) EA201890254A3 (ru)
EC (2) ECSP12011926A (ru)
ES (4) ES2754398T3 (ru)
GT (1) GT201200161A (ru)
HK (2) HK1172031A1 (ru)
HR (3) HRP20140780T4 (ru)
HU (2) HUE045784T2 (ru)
IL (4) IL310635A (ru)
LT (2) LT2796457T (ru)
MA (1) MA33838B1 (ru)
ME (1) ME02477B (ru)
MX (1) MX358345B (ru)
MY (2) MY160542A (ru)
NI (1) NI201200096A (ru)
NZ (3) NZ600155A (ru)
PE (2) PE20121337A1 (ru)
PH (1) PH12015502514A1 (ru)
PL (4) PL3133070T3 (ru)
PT (4) PT2796457T (ru)
RS (3) RS59543B1 (ru)
SG (2) SG10201800136QA (ru)
SI (3) SI2796457T1 (ru)
SM (1) SMT201600273B (ru)
TN (1) TN2012000237A1 (ru)
TW (3) TWI606827B (ru)
UA (1) UA113491C2 (ru)
WO (1) WO2011066352A1 (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006007560A2 (en) 2004-07-01 2006-01-19 University Of Pennsylvania Targeted protein replacement for the treatment of lysosomal storage disorders
SI2796457T1 (sl) 2009-11-27 2016-10-28 Genzyme Corporation Genz 112638 za zdravljenje Gaucherjeve ali Fabryjeve bolezni v kombinirani terapiji
EP2721151B1 (en) * 2011-06-20 2017-12-06 Mount Sinai School Of Medicine Anti-tnf-therapy for the mucopolysaccharidoses and other lysosomal disorders
HUE051021T2 (hu) 2011-09-07 2021-01-28 Sinai School Medicine Ceramidáz és sejtek differenciálódása
WO2013078413A1 (en) * 2011-11-22 2013-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulators of lipid storage
EP3679923B1 (en) 2012-06-01 2021-08-04 Icahn School of Medicine at Mount Sinai Ceramide levels in the treatment and prevention of infections
HUE046113T2 (hu) 2013-03-14 2020-02-28 Icahn School Med Mount Sinai Terápiás sav ceramidáz készítmények és azok elõállítási és felhasználási eljárásai
WO2015042397A1 (en) * 2013-09-20 2015-03-26 Biomarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
WO2016001885A2 (en) * 2014-07-03 2016-01-07 Dr. Reddy’S Laboratories Limited Amorphous form of eliglustat hemitartarate
WO2016166170A1 (en) 2015-04-14 2016-10-20 Sandoz Ag Crystalline eliglustat hydrochloride
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
CN108700594B (zh) 2015-11-18 2021-06-29 建新公司 多囊性肾病的生物标志物及其用途
CN107445938B (zh) * 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
CN106349210A (zh) * 2016-08-24 2017-01-25 北京阳光诺和药物研究有限公司 一种制备酒石酸艾力骨司坦的方法
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof
ZA201803719B (en) 2017-06-05 2019-04-24 Cipla Ltd Stable solid dispersions of eliglustat hemitartrate
BR112019026483A2 (pt) * 2017-06-16 2020-07-14 Beta Pharma, Inc. formulação farmacêutica de n-(2-(2-(dimetilamina)etoxi)-4-metoxi-5-((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amina)fenil)acrilamida e seus sais
US20200222310A1 (en) * 2017-08-08 2020-07-16 Kashiv Biosciences, Llc Pharmaceutical composition comprising eliglustat
US20200197366A1 (en) * 2017-08-08 2020-06-25 Kashiv Biosciences, Llc Pharmaceutical composition comprising eliglustat
IL275091B1 (en) 2017-12-15 2024-05-01 Genzyme Corp Methods for treating Gaucher's disease
WO2019123476A1 (en) * 2017-12-20 2019-06-27 Sarudbhava Formulations Private Limited Stable amorphous eliglustat premix and process for the preparation thereof
WO2019211778A2 (en) * 2018-05-02 2019-11-07 Kashiv Biosciences, Llc Pro-drugs of eliglustat
CN112512558A (zh) * 2018-05-27 2021-03-16 比奥阿赛斯技术有限公司 戈谢病的治疗
CN110878079A (zh) * 2018-12-31 2020-03-13 北京启慧生物医药有限公司 一种高纯度依利格鲁司他的制备方法
CN116120274A (zh) 2021-11-12 2023-05-16 曙方(上海)医药科技有限公司 依利格鲁司他可药用盐及其晶型

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311286D0 (en) 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
DE3522475A1 (de) 1985-06-22 1987-01-02 Kali Chemie Pharma Gmbh Neue aromatische verbindungen, ihre herstellung und verwendung
US5041441A (en) 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
ZA929008B (en) 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
US5302609A (en) 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
US5707649A (en) 1993-08-13 1998-01-13 Seikagaku Corporation Agent for treating neuronal diseases
US6309823B1 (en) 1993-10-26 2001-10-30 Affymetrix, Inc. Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same
AU691886B2 (en) 1994-02-02 1998-05-28 Transave, Inc. Pharmaceutically active compounds and liposomes, and methods of use thereof
AU698833B2 (en) 1994-06-10 1998-11-12 Seikagaku Corporation 2-acylaminopropanol compound and medical composition
FR2734819B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
WO1997010817A1 (en) 1995-09-20 1997-03-27 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6890949B1 (en) 1999-07-09 2005-05-10 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6255336B1 (en) 1995-09-20 2001-07-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20030073680A1 (en) 1995-09-20 2003-04-17 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
JP3993908B2 (ja) 1995-12-08 2007-10-17 生化学工業株式会社 アミノアルコール誘導体及び該誘導体の製造方法
NO965193L (no) 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP4140984B2 (ja) 1995-12-20 2008-08-27 生化学工業株式会社 分化誘導作用を有する薬剤
US5972928A (en) 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) 1997-06-06 2008-11-05 生化学工業株式会社 アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
WO2000006145A1 (en) 1998-07-27 2000-02-10 Johns Hopkins University Methods for treating conditions modulated by lactosylceramide
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
CA2378600A1 (en) * 1999-07-09 2001-01-18 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20040252299A9 (en) 2000-01-07 2004-12-16 Lemmo Anthony V. Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
NZ519984A (en) * 2000-01-07 2004-03-26 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
AU5721301A (en) 2000-04-24 2001-11-07 Teva Pharma Zolpidem hemitartrate
US6436987B1 (en) 2000-06-08 2002-08-20 Pfizer Inc. Crystalline forms of (3S-trans)-2-[3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)-benzoic acid
US20040260099A1 (en) 2001-01-10 2004-12-23 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO2002062777A2 (en) 2001-01-10 2002-08-15 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20020198240A1 (en) 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
US7148251B2 (en) 2001-01-10 2006-12-12 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
BR0116803A (pt) * 2001-01-18 2004-02-17 Merck Patent Gmbh Proteìnas de fusão bifuncionais com atividade de glicocerebrosidase
PT2266968E (pt) 2001-07-16 2013-02-25 Genzyme Corp Síntese de udp-glucose: inibidores de n-acil esfingosinaglucosiltransferase
EP1281755A3 (en) 2001-07-31 2003-06-18 Pfizer Products Inc. Variants of the human cyp2d6 gene
CA2459172C (en) 2001-08-08 2011-07-05 Takeda Chemical Industries, Ltd. Bicyclic compound, production and use thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US20060217560A1 (en) 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
WO2004004702A2 (en) 2002-07-09 2004-01-15 The Scripps Research Institute Method to inhibit ischemia and reperfusion injury
US20050032070A1 (en) 2003-08-05 2005-02-10 Sebastian Raimundo Polymorphisms in the human gene for CYP2D6 and their use in diagnostic and therapeutic applications
ATE504588T1 (de) * 2004-01-27 2011-04-15 Synthon Bv Stabile salze von olanzapin
CA2582022C (en) 2004-09-30 2021-05-18 Vanda Pharmaceuticals, Inc. Methods for the administration of iloperidone
CA2584246C (en) 2004-10-13 2011-08-09 Pharmacia & Upjohn Company Llc Crystalline forms of 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6h)-yl]-n-(2-hydroxyethyl)-4-methylbenzamide
EP1811991B1 (en) * 2004-11-10 2018-11-07 Genzyme Corporation Treatment of type 2 diabetes using inhibitors of glycosphingolipid synthesis
WO2007038676A2 (en) * 2005-09-28 2007-04-05 Teva Pharmaceutical Industries Ltd. Polymorphic forms of ladostigil tartrate
WO2007040995A1 (en) * 2005-10-03 2007-04-12 Mallinckrodt Inc. Process for preparing zolpidem hemitartrate and tartrate polymorphs
MX2007016179A (es) 2006-04-17 2008-03-11 Teva Pharma Formas cristalinas de o-desmetilvenlafaxina.
ES2546181T3 (es) * 2006-05-09 2015-09-21 Genzyme Corporation Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos
KR101271225B1 (ko) 2006-10-31 2013-06-03 삼성디스플레이 주식회사 발광 다이오드 칩 및 발광 다이오드 광원 모듈의 제조 방법
TWI314226B (en) 2006-12-07 2009-09-01 Ind Tech Res Inst Piezoelectricity-driving optical lens module
EP1961765A1 (en) 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
JP2010523578A (ja) 2007-03-30 2010-07-15 アミカス セラピューティックス インコーポレイテッド 薬理シャペロンを用いるファブリー病の治療方法
AU2008245578A1 (en) 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
EP2594564B1 (en) 2007-05-31 2016-09-28 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
DE102007029581B4 (de) 2007-06-26 2020-04-09 GM Global Technology Operations LLC (n. d. Ges. d. Staates Delaware) Kraftfahrzeugdach und Kraftfahrzeugkarosserie
EP2227780A4 (en) 2008-03-19 2011-08-03 Existence Genetics Llc GENETIC ANALYSIS
WO2009117150A2 (en) 2008-03-20 2009-09-24 Genzyme Corporation Method of treating lupus with ceramide derivatives
CN107115530A (zh) 2009-11-27 2017-09-01 勃林格殷格翰国际有限公司 基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗
CU24084B1 (es) 2009-11-27 2015-03-30 Bayer Ip Gmbh Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificación para uso como principio activo farmacéutico
FR2953139B1 (fr) 2009-11-27 2012-04-13 Servier Lab Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine
SI2796457T1 (sl) 2009-11-27 2016-10-28 Genzyme Corporation Genz 112638 za zdravljenje Gaucherjeve ali Fabryjeve bolezni v kombinirani terapiji
KR20140033432A (ko) 2011-06-21 2014-03-18 노파르티스 아게 (s)-피롤리딘-1,2-디카르복실산 2-아미드 1-(｛4-메틸-5-[2-(2,2,2-트리플루오로-1,1-디메틸-에틸)-피리딘-4-일]-티아졸-2-일｝-아미드)의 다형체
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
JP6728842B2 (ja) 2016-03-24 2020-07-22 オムロン株式会社 光学計測装置
CN107445938B (zh) 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof

Also Published As

Publication number Publication date
NZ600155A (en) 2014-10-31
TW201737910A (zh) 2017-11-01
HUE045784T2 (hu) 2020-01-28
MX2012006083A (es) 2012-06-19
HRP20191647T1 (hr) 2019-12-13
JP7150528B2 (ja) 2022-10-11
HUE029371T2 (en) 2017-02-28
EP3599237A1 (en) 2020-01-29
PL2796457T3 (pl) 2017-04-28
LT2796457T (lt) 2016-09-12
CY1122698T1 (el) 2021-03-12
KR20200013105A (ko) 2020-02-05
EA201890254A2 (ru) 2018-10-31
PL3599237T3 (pl) 2021-09-27
US20160120842A1 (en) 2016-05-05
EA201890254A3 (ru) 2019-02-28
EA029990B1 (ru) 2018-06-29
IL260299A (en) 2018-08-30
CN102712629B (zh) 2016-10-12
EA201592195A1 (ru) 2016-04-29
TWI586663B (zh) 2017-06-11
US20160166542A1 (en) 2016-06-16
US10888547B2 (en) 2021-01-12
KR20120115972A (ko) 2012-10-19
SI2504332T1 (sl) 2014-09-30
TWI656873B (zh) 2019-04-21
MY192644A (en) 2022-08-29
TW201130822A (en) 2011-09-16
WO2011066352A1 (en) 2011-06-03
PH12015502514A1 (en) 2016-08-15
CY1117996T1 (el) 2017-05-17
CA2781676C (en) 2020-05-05
KR20220162824A (ko) 2022-12-08
EA023923B1 (ru) 2016-07-29
EP3133070A1 (en) 2017-02-22
JP2016138124A (ja) 2016-08-04
AR121611A2 (es) 2022-06-22
HRP20161038T1 (hr) 2016-10-21
LT3133070T (lt) 2019-11-11
BR112012012947B8 (pt) 2021-05-25
BR112012012947A2 (pt) 2017-03-01
HK1172031A1 (en) 2013-04-12
IL310635A (en) 2024-04-01
CN112521366A (zh) 2021-03-19
CN105777707A (zh) 2016-07-20
JP6452635B2 (ja) 2019-01-16
MA33838B1 (fr) 2012-12-03
CN105753846B (zh) 2019-11-15
ES2875382T3 (es) 2021-11-10
EP2796457A1 (en) 2014-10-29
KR102073207B1 (ko) 2020-02-05
MX358345B (es) 2018-08-14
US20230172903A1 (en) 2023-06-08
HRP20140780T1 (en) 2014-11-07
EP2504332A1 (en) 2012-10-03
GT201200161A (es) 2014-01-27
JP2023116764A (ja) 2023-08-22
DK2504332T4 (da) 2021-06-07
PL2504332T5 (pl) 2021-08-23
NI201200096A (es) 2012-10-30
CL2012001348A1 (es) 2012-08-24
EP3599237B1 (en) 2021-03-24
CA3075788A1 (en) 2011-06-03
CY1115880T1 (el) 2017-01-25
EP2796457B1 (en) 2016-05-18
PT2504332E (pt) 2014-09-02
SI2796457T1 (sl) 2016-10-28
KR20180049255A (ko) 2018-05-10
AR121612A2 (es) 2022-06-22
CN112521367A (zh) 2021-03-19
HRP20140780T4 (hr) 2021-08-06
ES2493940T5 (es) 2021-11-23
NZ715108A (en) 2017-06-30
MY160542A (en) 2017-03-15
WO2011066352A8 (en) 2011-08-11
SMT201600273B (it) 2016-08-31
JP2015212291A (ja) 2015-11-26
CN112521367B (zh) 2024-01-02
RS53503B1 (en) 2015-02-27
SI3133070T1 (sl) 2019-11-29
AU2016202591A1 (en) 2016-05-19
CR20120277A (es) 2012-09-05
PT3599237T (pt) 2021-04-28
KR20150125734A (ko) 2015-11-09
UA113491C2 (xx) 2017-02-10
SG10201407881WA (en) 2015-01-29
JP2013512252A (ja) 2013-04-11
ES2586947T3 (es) 2016-10-19
ECSP18063798A (es) 2020-02-28
ES2754398T3 (es) 2020-04-17
HK1203485A1 (zh) 2015-10-30
PL3133070T3 (pl) 2020-01-31
US20210369672A1 (en) 2021-12-02
CA2781676A1 (en) 2011-06-03
CA3075788C (en) 2021-12-21
IL219892A0 (en) 2012-07-31
DK2504332T3 (da) 2014-08-25
JP6370264B2 (ja) 2018-08-08
US11458119B2 (en) 2022-10-04
CL2016002589A1 (es) 2017-05-19
NZ625712A (en) 2016-02-26
PE20121337A1 (es) 2012-10-12
TWI606827B (zh) 2017-12-01
US20210393590A1 (en) 2021-12-23
AU2017265180B2 (en) 2019-08-01
ES2493940T3 (es) 2014-09-12
US20130137743A1 (en) 2013-05-30
RS59543B1 (sr) 2019-12-31
AU2017265180A1 (en) 2017-12-14
BR112012012947B1 (pt) 2021-04-06
AR079152A1 (es) 2011-12-28
EP2504332B2 (en) 2021-03-17
ME02477B (me) 2017-02-20
JP2020189873A (ja) 2020-11-26
DOP2016000250A (es) 2017-02-15
AU2016202591B2 (en) 2017-11-30
EP3133070B1 (en) 2019-08-14
EP2504332B1 (en) 2014-06-04
RS53503B2 (sr) 2021-07-30
CN105777707B (zh) 2020-10-13
SG10201800136QA (en) 2018-02-27
PL2504332T3 (pl) 2014-10-31
CN102712629A (zh) 2012-10-03
TN2012000237A1 (en) 2013-12-12
ECSP12011926A (es) 2012-07-31
DOP2012000141A (es) 2012-09-30
AU2010324810B2 (en) 2016-05-12
CN105753846A (zh) 2016-07-13
PT3133070T (pt) 2019-11-11
DK3133070T3 (da) 2019-11-11
RS54978B1 (sr) 2016-11-30
CA3140959A1 (en) 2011-06-03
AU2010324810A1 (en) 2012-06-07
EP3896069A1 (en) 2021-10-20
IL283935A (en) 2021-07-29
TW201639562A (zh) 2016-11-16
SI2504332T2 (sl) 2021-08-31
PE20171255A1 (es) 2017-08-28
PT2796457T (pt) 2016-07-14
JP2019001809A (ja) 2019-01-10
DK2796457T3 (en) 2016-08-29

Similar Documents

Publication Publication Date Title
EA201270646A1 (ru) Ингибиторы глюкозилцерамидсинтазы
UA107951C2 (en) Imidazopyridine derivatives as inhibitors of jak
EA201190227A1 (ru) Оксазолзамещенные индазолы в качестве ингибиторов pi3-киназ
EA201201677A1 (ru) Производные гетероарилимидазолона в качестве ингибиторов jak
BRPI1009333B8 (pt) compostos inibidores de beta-secretase, seus usos, bem como composição farmacêutica
EA201301209A1 (ru) Производные пирролотриазинона в качестве ингибиторов p13k
EA201100030A1 (ru) Пиразольные соединения 436
EA201370166A1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
EA200970207A1 (ru) Соединения пиридо[2,3-d]пиримидинона и их применение в качестве pi3 ингибиторов
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
EA201200918A1 (ru) Производные пирролидин карбоновой кислоты как агонисты сопряженного с g-белком рецептора 43 (gpr43), фармацевтическая композиция и методы их использования при лечении метаболических нарушений
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
GEP20166481B (en) (crystalline forms of hydrochloride salt of (4a-r, 9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2, 3, 4, 4a, 9, 9a-hexa- hydro-1h-indeno [2, 1-b] pyridine-6-carbonitrile and their use as hsd 1 inhibitors
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX359069B (es) Sal y formas cristalinas de inhibidor de quinasa tipo polo-4.
EA201270302A1 (ru) Безводные формы производных пиридина
NO20092719L (no) Nye kromen-2-on-derivater og deres anvendelse som monoaminneurotransmitter-gjenopptaksinhibitorer
EA201201049A1 (ru) 5-алкинилпиримидины и их применение в качестве ингибиторов киназы
EA201001239A1 (ru) Замещённые пиперидины в качестве ингибиторов ренина
TH135901B (th) ตัวยับยั้งกลูโคซิลเซอราไมด์ ซินเธส
TN2013000150A1 (en) Co-crystals and salts of ccr3-inhibitors
TH106979A (th) อนุพันธ์ของแอลคิล พิริมิดิน-4-โอนที่ถูกแทนที่
TH106828B (th) สารยับยั้งไพร์โรโลไพราซีนคิเนส
EA201001240A1 (ru) Замещенные пиперидины в качестве ингибиторов ренина

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KZ